Through an exhaustive medicinal chemistry campaign, Buto sampled chemical diversity space among >100M NCEs, blanketing the Shc target to find the most effective scaffolds possible.
There are 5M people in the US with Alzheimer’s Disease. Shc protein and activity rises in the brains of AD patients, and A-beta amyloid stimulates Shc expression five-fold in innate immune cells. Shc inhibition ameliorates AD in animal models. Buto’s molecule ameliorates microglial inflammation and preserves memory in two animal models of AD.
Excessive fibrosis is responsible for about 40% of health care costs in the developed world. Buto's molecules reduce fibrosis in human IPF lung tissue. In the bleomycin lung fibrosis mouse model, Shc inhibitors outperform Ofev/Nintedanib. Buto’s molecules ameliorate liver fibrosis in multiple mouse models of NASH and ALD.
